Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 7.8%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 75,400 shares, a decline of 7.8% from the May 31st total of 81,800 shares. Based on an average daily trading volume, of 653,500 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Oppenheimer raised shares of Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, April 16th.

Institutional Investors Weigh In On Avalo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new stake in shares of Avalo Therapeutics during the third quarter valued at about $34,000. Affinity Asset Advisors LLC bought a new stake in shares of Avalo Therapeutics during the first quarter valued at about $218,000. Finally, Ikarian Capital LLC bought a new stake in shares of Avalo Therapeutics during the first quarter valued at about $1,015,000. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics Trading Down 5.1 %

Avalo Therapeutics stock traded down $0.62 during midday trading on Wednesday, reaching $11.64. The stock had a trading volume of 2,964 shares, compared to its average volume of 354,208. Avalo Therapeutics has a 12 month low of $3.95 and a 12 month high of $95.52. The firm’s 50-day moving average price is $12.27 and its 200 day moving average price is $9.55.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($5.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($4.80). Avalo Therapeutics had a negative net margin of 1,639.50% and a negative return on equity of 1,439.87%. As a group, research analysts anticipate that Avalo Therapeutics will post -0.91 EPS for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.